JP Morgan Maintains Overweight on TG Therapeutics, Raises Price Target to $72
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
JP Morgan analyst Brian Cheng maintains TG Therapeutics (NASDAQ:TGTX) with a Overweight and raises the price target from $65 to $72.
JP Morgan analyst Brian Cheng maintains TG Therapeutics (NASDAQ:TGTX) with a Overweight and raises the price target from $65 to $72.